Carnick & Kubik’s AbbVie ABBV Stock Holding History

Carnick & Kubik’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$674K	Buy	11,805 +365	+3%	+$20.3K	0.2%	138
2015 Q4	$678K	Buy	11,440 +522	+5%	+$30.1K	0.44%	76
2015 Q3	$594K	Buy	10,918 +840	+8%	+$54.7K	0.42%	90
2015 Q2	$677K	Sell	10,078 -222	-2%	-$14.5K	0.55%	67
2015 Q1	$603K	Sell	10,300 -325	-3%	-$19.6K	0.5%	80
2014 Q4	$695K	Buy	10,625 +500	+5%	+$31.5K	0.59%	59
2014 Q3	$585K	Sell	10,125 -975	-9%	-$54.1K	0.54%	65
2014 Q2	$626K	Buy	11,100 +325	+3%	+$17.1K	0.62%	56
2014 Q1	$554K	Sell	10,775 -200	-2%	-$10.1K	0.53%	64
2013 Q4	$580K	Buy	+10,975	New	+$539K	0.52%	66
2013 Q3	–	Sell	-10,130	Closed	-$419K	–	84
2013 Q2	$419K	Buy	+10,130	New	+$443K	0.52%	76

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Carnick & Kubik's ABBV Position: Q1 2016 in Review

Carnick & Kubik increased its AbbVie (ABBV) stake by 3.2% in Q1 2016, buying an estimated $20.3K and bringing the position to 11,805 shares worth $674K. The position accounts for 0.2% of the portfolio, ranked #138.

Carnick & Kubik first reported a position in ABBV in Q2 2013 and has held it in 11 quarters since. The position peaked at $695K in Q4 2014. 1,638 funds tracked by Wall St. Rank hold ABBV as of Q1 2016.

Carnick & Kubik held 11,805 shares of AbbVie worth $674K as of Q1 2016.
Carnick & Kubik bought 365 AbbVie shares in Q1 2016, an estimated $20.3K.
AbbVie made up 0.2% of Carnick & Kubik's portfolio in Q1 2016, its #138 holding.
Carnick & Kubik first reported a position in AbbVie in Q2 2013 and has held it in 11 quarters since.
Carnick & Kubik's AbbVie position peaked at $695K in Q4 2014.
1,638 funds tracked by Wall St. Rank held AbbVie as of Q1 2016.

Based on Carnick & Kubik's 13F filing for Q1 2016, filed 12 May 2016.